Jeffrey I. Weitz

Oct 18, 2024 | emjreviews.com | Jeffrey I. Weitz

The emerging class of agents targeting factor XI/XIa offers the paradigm-shifting possibility of ‘haemostasis-sparing anticoagulation’: protection from stroke and other thromboembolic events with a benign bleeding profile. With three investigational agents now into late-phase development, two presentations delivered at the European Society of Cardiology (ESC) Congress 2024, held in London, UK, have added to our knowledge of this innovative and diverse class.

Sep 14, 2023 | emjreviews.com | Shaun G. Goodman |Jeffrey I. Weitz

IntroductionShaun G. GoodmanShaun G.

Jun 3, 2023 | pubmed.ncbi.nlm.nih.gov | Eikelboom JW |John Eikelboom |Jeffrey I. Weitz |Weitz JI

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software